MedPath

Neosil, Inc.

Neosil, Inc. logo
🇺🇸United States
Ownership
Private, Subsidiary
Established
2004-01-01
Employees
-
Market Cap
-
Website
http://www.neosil.com

Clinical Trials

2

Active:0
Completed:1

Trial Phases

1 Phases

Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (100.0%)

Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss

Phase 2
Conditions
Androgenetic Alopecia
Interventions
Drug: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
First Posted Date
2007-05-10
Last Posted Date
2008-05-20
Lead Sponsor
Neosil, Inc.
Target Recruit Count
140
Registration Number
NCT00471510
Locations
🇩🇪

bioskin Institute for Dermatological Research and Development GmbH, Hamburg, Germany

Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss

Phase 2
Completed
Conditions
Androgenetic Alopecia
Interventions
Drug: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
First Posted Date
2007-01-05
Last Posted Date
2008-05-20
Lead Sponsor
Neosil, Inc.
Target Recruit Count
180
Registration Number
NCT00418730
Locations
🇩🇪

bioskin Institute for Dermatological Research and Development GmbH, Hamburg, Germany

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.